Outcome of Second Primary Malignancies Developing in Multiple Myeloma Patients

被引：6

作者：

Avivi, Irit ^{[1
,2
]}

Vesole, David H. ^{[3
]}

Davila-Valls, Julio ^{[4
]}

Usnarska-Zubkiewicz, Lidia ^{[5
]}

Olszewska-Szopa, Magdalena ^{[5
]}

Milunovic, Vibor ^{[6
]}

Baumert, Bartlomiej ^{[7
]}

Osekowska, Bogumila ^{[7
]}

Kopinska, Anna ^{[8
]}

Gentile, Massimo ^{[9
,10
]}

Puertas-Martinez, Borja ^{[11
]}

Robak, Pawel ^{[12
]}

Crusoe, Edvan ^{[13
]}

Rodriguez-Lobato, Luis Gerardo ^{[14
]}

Gajewska, Malgorzata ^{[15
]}

Varga, Gergely ^{[16
]}

Delforge, Michel ^{[17
]}

Cohen, Yael ^{[1
,2
]}

Gozzetti, Alessandro ^{[18
]}

Pena, Camila ^{[19
]}

Shustik, Chaim ^{[20
]}

Mikala, Gabor ^{[21
]}

Zalac, Klara ^{[22
]}

Alexander, H. Denis ^{[23
]}

Barth, Peter ^{[24
]}

Weisel, Katja ^{[25
]}

Martinez-Lopez, Joaquin ^{[26
]}

Waszczuk-Gajda, Anna ^{[27
]}

Krzystanski, Mateusz

Jurczyszyn, Artur ^{[28
]}

机构：

[1] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, Dept Rheumatol, IS-6997801 Tel Aviv, Israel

[2] Tel Aviv Univ, Fac Med, IL-6997801 Tel Aviv, Israel

[3] Hackensack Univ, Med Ctr, Rutgers New Jersey Med Sch, Hackensack, NJ 07601 USA

[4] Hosp Nuestra Senora Sonsoles, Secc Neumol, Avila 05004, Spain

[5] Wroclaw Med Univ, Dept Hematol Blood Neoplasms & Bone Marrow Transpl, PL-50556 Wroclaw, Poland

[6] Clin Hosp Merkur, Div Hematol, Zagreb 10000, Croatia

[7] Pomeranian Med Univ, Dept Gen Pathol, PL-70121 Szczecin, Poland

[8] Med Univ Silesia, Dept Hematol & Bone Marrow Transplantat, PL-40032 Katowice, Poland

[9] AO Cosenza, Hematol Unit, Cosenza, Italy

[10] Univ Calabria, Dept Pharm Hlth & Nutr Sci, I-87036 Arcavacata Di Rende, Italy

[11] Univ Hosp Salamanca, Canc Res Ctr, Inst Invest Biomed Salamanca IBSAL, CIBERONC,IBMCC,USAL,CSIC, Salamanca 37007, Spain

[12] Med Univ Lodz, Copernicus Mem Hosp, Dept Hematol, PL-90752 Lodz, Poland

[13] Univ Fed Bahia, Hosp Univ Prof Edgar Santos, Serv Hematol, BR-40110909 Salvador, BA, Brazil

[14] Hosp Clin Barcelona, Dept Hematol, Amyloidosis & Multiple Myeloma Unit, IDIBAPS, Barcelona 08036, Spain

[15] Mil Inst Med, Dept Internal Med & Hematol, PL-04141 Warsaw, Poland

[16] Semmelweis Univ, Dept Internal Med & Haematol, H-1085 Budapest, Hungary

[17] Univ Hosp UZ Leuven, Dept Pathol, Univ Hosp, B-3000 Leuven, Belgium

[18] Univ Siena, Dept Med Sci Surg & Neurosci, I-53100 Siena, Italy

[19] Hosp Salvador, Secc Hematol, Santiago, Chile

[20] McGill Univ, Royal Victoria Hosp, Urol Dept, Hlth Ctr, Montreal, PQ H4A 3J1, Canada

[21] South Pest Cent Hosp, Natl Inst Hematol & Infect Dis, Dept Hematol & Stem Cell Transplantat, H-1097 Budapest, Hungary

[22] Univ Hosp Ctr Sestre Milosrdnice, Dept Hematol, Clin Internal Med, Zagreb 10000, Croatia

[23] Ulster Univ, Personalised Med Ctr, Sch Med, Derry Londonderry BT47 6SB, North Ireland

[24] Brown Univ, Warren Alpert Med Sch, Dept Med, Providence, RI 02912 USA

[25] Univ Med, Ctr Hamburg Eppendorf, Dept Oncol Hematol & Bone Marrow Transplantat, Sect Pneumol, D-20246 Hamburg, Germany

[26] Nieves Lopez Munoz Hosp, Madrid 28029, Spain

[27] Warsaw Med Univ, Dept Hematol Oncol & Internal Dis, PL-02097 Warsaw, Poland

[28] Jagiellonian Univ Med Coll, Dept Hematol, PL-31155 Krakow, Poland

来源：

CANCERS | 2023年 / 15卷 / 17期

关键词：

second primary malignancy; SPM; multiple myeloma; therapy; LENALIDOMIDE; TRANSPLANTATION; THERAPY;

D O I：

10.3390/cancers15174359

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: There is an increased risk of second primary malignancies (SMPs) in patients with multiple myeloma (MM). This multinational 'real-world' retrospective study analyzed the characteristics and outcomes of MM patients that developed SPMs.Results: 165 patients were analyzed: 62.4% males; 8.5% with a prior cancer; 113 with solid SPMs, mainly =stage 2; and 52 with hematological SPM (hemato-SPM), mainly MDS/AML. Patients with hemato-SPM were younger (p = 0.05) and more frequently had a prior AutoHCT (p = 0.012). The time to SPM was shorter in the older (>65 years) and more heavily pretreated patients. One hundred patients were actively treated at the time of SPM detection. Treatment was discontinued in 52, substituted with another anti-MM therapy in 15, and continued in 33 patients. Treatment discontinuation was predominant in the patients diagnosed with hemato-SPM (76%). The median OS following SPM detection was 8.5 months, and the main cause of death was SPM. A poor ECOG status predicted a shorter OS (PS 3 vs. 0, HR = 5.74, 2.32-14.21, p < 0.001), whereas a normal hemoglobin level (HR = 0.43, 0.19-0.95, p = 0.037) predicted longer OS.Conclusions: With the continuing improvement in OS, a higher proportion of MM patients might develop SPM. The OS following SPM diagnosis is poor; hence, frequent surveillance and early detection are imperative to improve outcomes.

引用

页数：14